Novavax Global Commercial Operations and COVID-19 Vaccine Update
Cautionary note regarding forward-looking statements
This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect,"
"plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various
matters including information relating to the future of Novavax, its key strategic priorities and commercial goals, its operating plans, objectives and prospects, including, its
future financial or business performance, conditions, or strategy, including expectations regarding first half 2023 SG&A and R&D expense run rate, its future product demand
trends, its partnerships, its ability to deliver a competitive bivalent or monovalent vaccine product for the Fall 2023 vaccine season, the ongoing development of our vaccine
candidates, including strain selection, anticipated timing of clinical trials and expected results, the ongoing development of NVX-COV2373, a COVID-19-Influenza combination
vaccine candidate and other vaccine candidates, the scope, timing and outcome of future regulatory filings and actions, the efficacy, safety and intended utilization of NVX-
COV2373 and Novavax's other vaccine candidates, the global market opportunities for our vaccine candidates, our manufacturing capacity and the future availability of
Novavax's vaccine candidates and key upcoming milestones.
Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or
implied by such statement. Applicable risks and uncertainties include, among others, challenges satisfying, alone or together with partners, various safety, efficacy, and
product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; Novavax's
ability to continue as a going concern within one year after the issuance date of the financial statements for the year ended December 31, 2022; difficulty obtaining scarce
raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways;
unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental,
and other entities; manufacturing delays or challenges, including as a result of the timing of the anticipated regulatory requirements for the fall 2023 vaccination season; the
loss of future funding from the U.S. government; the potential for an unfavorable outcome in disputes, including the pending arbitration with Gavi and the risks identified under
the heading "Risk Factors" in Novavax's most recent Annual Report on Form 10-K and subsequent Form 10-Qs, as well as subsequent filings with the Securities and Exchange
Commission. Novavax cautions investors not to place considerable reliance on the forward-looking statements contained in this presentation. Investors are encouraged to
read Novavax's filings with the Securities and Exchange Commission, available at www.sec.gov and on our website at www.novavax.com, for a discussion of these and other
risks and uncertainties.
The forward-looking statements in this presentation speak only as of the date of this presentation, and we undertake no obligation to update or revise any of these statements.
Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to
these risks and uncertainties.
Novavax™ (and all associated logos) is a trademark of Novavax, Inc. Matrix-MTM is a trademark of Novavax AB.
novavax
© 2023 NOVAVAX. All rights reserved.
2View entire presentation